文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急诊科快速序贯插管:琥珀胆碱与罗库溴铵的首过成功率比较

Emergency Department Intubation Success With Succinylcholine Versus Rocuronium: A National Emergency Airway Registry Study.
PubMed 文献 · Ann Emerg Med · 2018-05-07
一句话结论在多中心急诊插管登记研究中,琥珀胆碱与罗库溴铵的首过插管成功率和不良事件发生率均无显著差异。

该研究基于国家急诊气道登记库(22个急诊科)的前瞻性数据,纳入2016年接受琥珀胆碱或罗库溴铵的快速序贯插管患者(>14岁),比较两种神经肌肉阻滞剂的首过插管成功率及围插管不良事件。结果显示,琥珀胆碱组首过成功率87.0%,罗库溴铵组87.5%(调整OR 0.9,95%CI 0.6–1.3);任何不良事件发生率分别为14.7%和14.8%(调整OR 1.1,95%CI 0.9–1.3)。按体重剂量分层后结果相似。结论认为,在大规模观察性数据中未发现神经肌肉阻滞剂选择与首过插管成功或围插管不良事件存在关联。

要点

  • 在22个急诊科的前瞻性登记数据中,琥珀胆碱组首过插管成功率87.0%,罗库溴铵组87.5%(调整OR 0.9,95%CI 0.6–1.3),无显著差异。
  • 任何不良事件发生率琥珀胆碱组14.7%,罗库溴铵组14.8%(调整OR 1.1,95%CI 0.9–1.3),两组相当。
  • 按体重剂量分层后,首过成功率和不良事件结果与总体一致。
  • 接受琥珀胆碱的患者更年轻,更常使用视频喉镜,且操作者经验更丰富。
  • 该研究为观察性设计,未检测到神经肌肉阻滞剂选择与首过插管成功或围插管不良事件的关联。

适用人群与场景

  • 2016年期间在22个急诊科接受快速序贯插管的患者,年龄大于14岁,且使用了琥珀胆碱或罗库溴铵。

研究设计与关键结果

  • 研究类型:基于国家急诊气道登记库的前瞻性多中心观察性研究,纳入22个急诊科,琥珀胆碱组2275例,罗库溴铵组1800例。
  • 主要终点:首过插管成功率琥珀胆碱组87.0% vs 罗库溴铵组87.5%,调整OR 0.9(95%CI 0.6–1.3)。
  • 关键次要终点:任何不良事件发生率琥珀胆碱组14.7% vs 罗库溴铵组14.8%,调整OR 1.1(95%CI 0.9–1.3)。
  • 按体重剂量分层后,首过成功率和不良事件结果与总体相似。
  • 组间特征:接受琥珀胆碱的患者更年轻,更可能使用视频喉镜,操作者经验更丰富。

证据类型、等级与局限

  • 证据类型:前瞻性多中心观察性登记研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该观察性数据未检测到琥珀胆碱与罗库溴铵在首过插管成功率或围插管不良事件上的关联,提示两种药物均可用于急诊快速序贯插管。
  • 选择神经肌肉阻滞剂时需考虑患者个体因素,因两组在年龄、喉镜类型和操作者经验上存在差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: Although both succinylcholine and rocuronium are used to facilitate emergency department (ED) rapid sequence intubation, the difference in intubation success rate between them is unknown. We compare first-pass intubation success between ED rapid sequence intubation facilitated by succinylcholine versus rocuronium.

METHODS: We analyzed prospectively collected data from the National Emergency Airway Registry, a multicenter registry collecting data on all intubations performed in 22 EDs. We included intubations of patients older than 14 years who received succinylcholine or rocuronium during 2016. We compared the first-pass intubation success between patients receiving succinylcholine and those receiving rocuronium. We also compared the incidence of adverse events (cardiac arrest, dental trauma, direct airway injury, dysrhythmias, epistaxis, esophageal intubation, hypotension, hypoxia, iatrogenic bleeding, laryngoscope failure, laryngospasm, lip laceration, main-stem bronchus intubation, malignant hyperthermia, medication error, pharyngeal laceration, pneumothorax, endotracheal tube cuff failure, and vomiting). We conducted subgroup analyses stratified by paralytic weight-based dose.

RESULTS: There were 2,275 rapid sequence intubations facilitated by succinylcholine and 1,800 by rocuronium. Patients receiving succinylcholine were younger and more likely to undergo intubation with video laryngoscopy and by more experienced providers. First-pass intubation success rate was 87.0% with succinylcholine versus 87.5% with rocuronium (adjusted odds ratio 0.9; 95% confidence interval 0.6 to 1.3). The incidence of any adverse event was also comparable between these agents: 14.7% for succinylcholine versus 14.8% for rocuronium (adjusted odds ratio 1.1; 95% confidence interval 0.9 to 1.3). We observed similar results when they were stratified by paralytic weight-based dose.

CONCLUSION: In this large observational series, we did not detect an association between paralytic choice and first-pass rapid sequence intubation success or peri-intubation adverse events.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. April MD, Arana A, Pallin DJ, et al. Emergency Department Intubation Success With Succinylcholine Versus Rocuronium: A National Emergency Airway Registry Study. Ann Emerg Med. 2018. PMID: 29747958. doi:10.1016/j.annemergmed.2018.03.042

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。